0001127602-15-004456.txt : 20150205 0001127602-15-004456.hdr.sgml : 20150205 20150205114041 ACCESSION NUMBER: 0001127602-15-004456 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150203 FILED AS OF DATE: 20150205 DATE AS OF CHANGE: 20150205 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PAREXEL INTERNATIONAL CORP CENTRAL INDEX KEY: 0000799729 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 042776269 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 195 WEST ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7814879900 MAIL ADDRESS: STREET 1: 195 WEST ST CITY: WALTHAM STATE: MA ZIP: 02451 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Saarony Gadi CENTRAL INDEX KEY: 0001552687 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21244 FILM NUMBER: 15578754 MAIL ADDRESS: STREET 1: C/O PAREXEL INTERNATIONAL STREET 2: 195 WEST STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2015-02-03 0000799729 PAREXEL INTERNATIONAL CORP PRXL 0001552687 Saarony Gadi C/O PAREXEL INTERNATIONAL 195 WEST STREET WALTHAM MA 02451 1 Corp. Sr. VP, CRS Common Stock 2015-02-03 4 M 0 6200 20.26 A 17300 D Common Stock 2015-02-03 4 M 0 2325 30.64 A 19625 D Common Stock 2015-02-03 4 S 0 8525 60.97 D 11100 D Stock Option (Right to Buy) 20.26 2015-02-03 4 M 0 6200 0 D 2019-09-21 Common Stock 6200 6200 D Stock Option (Right to Buy) 30.64 2015-02-03 4 M 0 2325 0 D 2020-09-19 Common Stock 2325 4650 D This transaction was executed in multiple trades through a trade order executed by a broker-dealer at prices ranging from $60.96- $61.04. The price reported in this column reflects the weighted average sale price. For all transactions reported on this Form 4 utilizing a weighted average sale price, the reporting person will provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price. Options become exercisable in increments of 25% of the total shares granted commencing on the first anniversary of the date of grant. /s/ W. Brett Davis, Attorney-in-fact 2015-02-05